Should I buy or sell Pacira BioSciences stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PCRX shares. View PCRX analyst ratings or view top-rated stocks .

What is Pacira BioSciences' stock price target for 2024?

9 Wall Street analysts have issued 1 year price targets for Pacira BioSciences' stock. Their PCRX share price targets range from $42.00 to $60.00. On average, they predict the company's share price to reach $52.36 in the next twelve months. This suggests a possible upside of 89.3% from the stock's current price. View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts .

How have PCRX shares performed in 2023?

Pacira BioSciences' stock was trading at $38.61 on January 1st, 2023. Since then, PCRX stock has decreased by 28.4% and is now trading at $27.66. View the best growth stocks for 2023 here .

When is Pacira BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our PCRX earnings forecast .

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) released its quarterly earnings data on Thursday, November, 2nd. The company reported $0.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by $0.13. The business had revenue of $163.93 million for the quarter, compared to analyst estimates of $172.83 million. Pacira BioSciences had a net margin of 1.05% and a trailing twelve-month return on equity of 12.16%.

What ETFs hold Pacira BioSciences' stock?

ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP) , SPDR S&P Pharmaceuticals ETF (XPH) , Invesco S&P SmallCap Health Care ETF (PSCH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) . iShares U.S. Pharmaceuticals ETF (IHE) .

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com . Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD) , NVIDIA (NVDA) , Micron Technology (MU) , ACADIA Pharmaceuticals (ACAD) , Skyworks Solutions (SWKS) , AbbVie (ABBV) , Pfizer (PFE) , QUALCOMM (QCOM) , Exelixis (EXEL) and Tesla (TSLA) .

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.53%), Clearbridge Investments LLC (2.48%), Rock Springs Capital Management LP (2.27%), Rice Hall James & Associates LLC (2.09%), Schroder Investment Management Group (1.44%) and Jennison Associates LLC (1.34%). Insiders that own company stock include Andreas Wicki , Anthony Molloy, Charles A Reinhart III , Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, David M Stack , Donald C Manning , Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams , Lauren Bullaro Riker , Mark A Kronenfeld, Mark Froimson, Max Reinhardt , Paul J Hastings and Roy Winston . View institutional ownership trends .

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

Pacira BioSciences Stock Price, News & Analysis (NASDAQ:PCRX)

$27.66

-1.03 (-3.59%)

(As of 12/6/2023 ET)

Compare

Today's Range: $27.53
▼
$28.94
50-Day Range: $26.32
▼
$31.49
52-Week Range: $25.93
▼
$48.60

Volume: 337,938 shs
Average Volume: 541,560 shs
Market Capitalization: $1.28 billion

P/E Ratio: 307.33
Dividend Yield: N/A
Price Target: $52.36

Pacira BioSciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.89 Rating Score
Upside/Downside: 89.3% Upside
$52.36 Price Target
Short Interest: Healthy
6.87% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.89
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 33.33%
From $2.16 to $2.88 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

105th out of 957 stocks

Pharmaceutical Preparations Industry

23rd out of 399 stocks

4.4

Analyst's Opinion

Consensus Rating
Pacira BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $52.36, Pacira BioSciences has a forecasted upside of 89.3% from its current price of $27.66.
Amount of Analyst Coverage
Pacira BioSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
6.87% of the outstanding shares of Pacira BioSciences have been sold short.
Short Interest Ratio / Days to Cover
Pacira BioSciences has a short interest ratio ("days to cover") of 6.4.
Change versus previous month
Short interest in Pacira BioSciences has recently decreased by 11.14%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Pacira BioSciences does not currently pay a dividend.
Dividend Growth
Pacira BioSciences does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pacira BioSciences has received a 52.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Bupivacaine", "Cryotherapy devices", and "Drug delivery devices" products. See details.
Environmental Sustainability
The Environmental Impact score for Pacira BioSciences is -1.89.

0.6

News and Social Media Coverage

Search Interest
Only 4 people have searched for PCRX on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.
MarketBeat Follows
5 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pacira BioSciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.60% of the stock of Pacira BioSciences is held by insiders.
Percentage Held by Institutions
99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Pacira BioSciences are expected to grow by 33.33% in the coming year, from $2.16 to $2.88 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pacira BioSciences is 307.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 116.77.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pacira BioSciences is 307.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 109.52.
Price to Book Value per Share Ratio
Pacira BioSciences has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pacira BioSciences Stock (NASDAQ:PCRX)

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

PCRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PCRX Stock News Headlines

November 13, 2023 | finance.yahoo.com

Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion

November 10, 2023 | markets.businessinsider.com

Pacira Announces FDA Approval Of Expanded EXPAREL Label To Include Two Addl Nerve Block Indications

December 7, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 10, 2023 | finance.yahoo.com

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

November 7, 2023 | finance.yahoo.com

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November

November 4, 2023 | finance.yahoo.com

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call Transcript

November 4, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)

November 3, 2023 | finance.yahoo.com

Are Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

December 7, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.

November 2, 2023 | finance.yahoo.com

Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated

November 2, 2023 | seekingalpha.com

Pacira BioSciences, Inc. 2023 Q3 - Results - Earnings Call Presentation

November 2, 2023 | finance.yahoo.com

Pacira BioSciences Inc (PCRX) Reports Q3 2023 Financial Results

November 2, 2023 | finance.yahoo.com

Pacira BioSciences Reports Third Quarter 2023 Financial Results

November 2, 2023 | seekingalpha.com

Pacira BioSciences: Preparing For A Pivotal Q3 Earnings

October 30, 2023 | seekingalpha.com

Pacira BioSciences: Sell-Off On Pain Relief Specialist - But Recovery Not Guaranteed

October 26, 2023 | finance.yahoo.com

Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023

October 24, 2023 | msn.com

Barclays Maintains Pacira BioSciences (PCRX) Overweight Recommendation

October 12, 2023 | finance.yahoo.com

American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.

October 6, 2023 | finance.yahoo.com

Loss-making Pacira BioSciences (NASDAQ:PCRX) sheds a further US$83m, taking total shareholder losses to 50% over 3 years

October 4, 2023 | msn.com

RBC Capital Reiterates Pacira BioSciences (PCRX) Outperform Recommendation

October 2, 2023 | finance.yahoo.com

American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care

September 27, 2023 | finance.yahoo.com

Unveiling Pacira BioSciences (PCRX)'s Value: Is It Really Priced Right? A Comprehensive Guide

September 27, 2023 | finance.yahoo.com

Unraveling the Future of Pacira BioSciences Inc (PCRX): A Deep Dive into Key Metrics

September 26, 2023 | marketwatch.com

Pacira BioSciences Chairman, CEO David Stack to Retire

September 26, 2023 | msn.com

Pacira BioSciences CEO David Stack to step down

September 26, 2023 | finance.yahoo.com

Pacira BioSciences Announces Leadership Succession Plan

September 6, 2023 | finance.yahoo.com

Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference

See More Headlines

Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:PCRX
CUSIP: 69512710
CIK: 1396814
Web: www.pacira.com
Phone: (813) 553-6680
Fax: 302-655-5049
Employees: 715
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $52.36
High Stock Price Target: $60.00
Low Stock Price Target: $42.00
Potential Upside/Downside: +89.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.09
Trailing P/E Ratio: 307.33
Forward P/E Ratio: 12.81
P/E Growth: N/A
Net Income: $15.91 million
Net Margins: 1.05%
Pretax Margin: 1.49%
Return on Equity: 12.16%
Return on Assets: 6.16%

Debt

Debt-to-Equity Ratio: 0.62
Current Ratio: 4.78
Quick Ratio: 3.74

Sales & Book Value

Annual Sales: $666.82 million
Price / Sales: 1.93
Cash Flow: $4.00 per share
Price / Cash Flow: 6.92
Book Value: $16.89 per share
Price / Book: 1.64

Miscellaneous

Outstanding Shares: 46,440,000
Free Float: 43,373,000
Market Cap: $1.28 billion
Optionable: Optionable
Beta: 0.72

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. David M. Stack (Age 73)
Chairman & CEO
Comp: $1.54M
Mr. Charles A. Reinhart III (Age 62)
CPA, M.B.A., Chief Financial Officer
Comp: $780.58k
Mr. Daryl Gaugler (Age 61)
Chief Operating Officer
Comp: $778.77k
Ms. Kristen Williams J.D. (Age 49)
Chief Administrative Officer & Secretary
Comp: $799.63k
Mr. Anthony Molloy III (Age 49)
Esq., Chief Legal & Compliance Officer
Comp: $581.41k
Ms. Lauren Bullaro Riker (Age 44)
Principal Accounting Officer & VP of Finance
Comp: $288.81k
Susan Mesco
Head of Investor Relations
Mr. Richard Kahr
Vice President of Human Resources
Dr. Roy Winston M.D. (Age 62)
Chief Medical Officer & Orthopedic Franchise
Comp: $996.94k
Mr. Dennis McLoughlin (Age 57)
Chief Customer Officer
Comp: $535.87k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PCRX shares.
View PCRX analyst ratings or view top-rated stocks.
What is Pacira BioSciences' stock price target for 2024?: 9 Wall Street analysts have issued 1 year price targets for Pacira BioSciences' stock. Their PCRX share price targets range from $42.00 to $60.00. On average, they predict the company's share price to reach $52.36 in the next twelve months. This suggests a possible upside of 89.3% from the stock's current price.
View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts.
How have PCRX shares performed in 2023?: Pacira BioSciences' stock was trading at $38.61 on January 1st, 2023. Since then, PCRX stock has decreased by 28.4% and is now trading at $27.66.
View the best growth stocks for 2023 here.
When is Pacira BioSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our PCRX earnings forecast.
How were Pacira BioSciences' earnings last quarter?: Pacira BioSciences, Inc. (NASDAQ:PCRX) released its quarterly earnings data on Thursday, November, 2nd. The company reported $0.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by $0.13. The business had revenue of $163.93 million for the quarter, compared to analyst estimates of $172.83 million. Pacira BioSciences had a net margin of 1.05% and a trailing twelve-month return on equity of 12.16%.
What ETFs hold Pacira BioSciences' stock?: ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What is Dave Stack's approval rating as Pacira BioSciences' CEO?: 54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Pacira BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).
Who are Pacira BioSciences' major shareholders?: Pacira BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.53%), Clearbridge Investments LLC (2.48%), Rock Springs Capital Management LP (2.27%), Rice Hall James & Associates LLC (2.09%), Schroder Investment Management Group (1.44%) and Jennison Associates LLC (1.34%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends.
How do I buy shares of Pacira BioSciences?: Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PCRX) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pacira BioSciences Stock Price, News & Analysis (NASDAQ:PCRX)

Pacira BioSciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Pacira BioSciences Stock (NASDAQ:PCRX)

PCRX Stock Price History

PCRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PCRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™